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Thiourea and guanidine units are found in nature, medicine, and materials. Their continued 
exploration in applications as diverse as cancer therapy, sensors, and electronics means that their 
toxicity is an important consideration. We have systematically synthesised a set of thiourea 
compounds and their guanidine analogues, and elucidated structure-activity relationships in terms of 
cellular toxicity in three ovarian cancer cell lines and their cisplatin-resistant sub-lines. We have been 
able to use the intrinsic luminescence of iridium complexes to visualise the effect of both structure 
alteration and cellular resistance mechanisms. These findings provide starting points for the 
development of new drugs and consideration of safety issues for novel thiourea- and guanidine-based 
materials. 
Introduction 
Thiourea and guanidine derivatives are versatile compounds that have previously been synthesised 
for use in a variety of industries from materials manufacturing to medical research. The two functional 
groups represent modifications of urea, with the oxygen being replaced by a sulfur, or by an NH unit, 
respectively. Compared to urea, thioureas are more acidic and poorer hydrogen bond acceptors. In 
contrast, guanidines are basic and protonated under most aqueous conditions (pKa = 13.6 for 
unsubstituted guanidine). While urea is of low toxicity (oral LD50 in rats of 8471 mg/kg1), showing only 
irritant properties at high concentrations, guanidine is listed as harmful, with an LD50 of 1120 mg/kg 
for the hydrochloride.2 Thiourea (LD50 of 1750 mg/kg) is a carcinogen and teratogen and has harmful 
effects on the thyroid.3 
Guanidines occur in biology in the form of the nucleobase guanine and the amino acid arginine, and 
are also found in urine.4,5 These compounds have also been employed in the catalytic synthesis in 
green chemistry,6 as potential antivirals for the treatment of poliovirus,7 and as adhesive promotors 
in the materials industry.8 We are currently investigating guanidine-based molecules as components 
in advanced organic LED materials.9 A focal point of guanidine research has been in medicinal 
chemistry. For example, metformin (N,N-dimethylbiguanide) is widely used in the treatment of type 2 
diabetes.10 Further research has been conducted on their antimicrobial and anticancer properties.11–
13 In these cases, the compounds studied included chalcones14 and also platinum centred derivatives.15 
Findings like these support advances in synthesising further derivatives of guanidine compounds to 
target new areas of cancer therapeutics, and further illustrate the biological importance of these 
simple and easily manipulatable structures.  
Compared to guanidines, thioureas are found more rarely, for example in 2-thiouridine in tRNAs.16 
Within chemistry, interest has centred on their hydrogen bonding capability which has enabled 
sensing of anions,17 self-assembly,18 and organocatalysis,19 for example. The thiourea functional group 
has been used widely in medicine, with 2-thiouracil itself used to treat thyroid disorders for some 
time.20 Thioureas are investigated as antiviral agents,21 including non-nucleoside HIV-1 reverse 
transcriptase inhibitors,22 insecticidal growth regulators,23 anti-inflammatory,23 and anticancer 
drugs.21  Thioureas show promise as anticancer drug candidates due to their sulfur atoms,24 with sulfur 
itself being a versatile and biologically important element to all living organisms.25 Thiourea derivatives 
have been synthesised with an assortment of partnering organic structures and demonstrated to exert 
anti-cancer effects in human cancer cell lines from different entities including breast and lung cancer 
as well as leukaemia26–28 29 
Given the broad application of guanidines and thioureas in upcoming drugs and materials, their 
toxicity is of interest both from the standpoint of potentially beneficial or detrimental effects. In this 
light, we decided to perform a systematic screen of a series of thiourea and guanidine compounds for 
toxicity in ovarian cancer cell lines, including those which display resistance to cisplatin, the mainstay 
of ovarian cancer therapies and one of the most commonly used anticancer drugs.30,31 These studies 
identify trends which could be used as first pointers for initial toxicity predictions of similar compounds. 
We have also been able to make use of the intrinsic luminescence of iridium complexes to observe 
extent and distribution of uptake, and its relationship to guanidine or thiourea function. 
  


























1S R = n-Pr, 63%
2S R = n-Bu, 56%
3S R = n-C6H13, 81%








1N R = n-Pr, 44%
2N R = n-Bu, 65%
3N R = n-C6H13, 45%




































Scheme 1. Synthesis of guanidine and thiourea compounds and their iridium complexes. 
A series of guanidine and thiourea compounds was synthesised based upon a 2-aminobenzimidazole 
unit; this was selected since it is a ‘drug-like’ unit which also has capacity to form the type of metal 
complexes which could be used in OLED materials. Monosubstitution of 1,1’-thiocarbonyldiimidazole 
was achieved by reaction with substoichiometric 2-aminobenzimidazole in acetonitrile. The second 
imidzoyl unit was displaced by a selection of amines (n-propylamine, n-butylamine,32 n-hexylamine, 
and benzylamine) in the presence of dimethylaminopyridine (DMAP) in dimethylformamide (DMF) to 
give compounds 1S to 4S in 63 - 81 % yield after purification.22 Portions of these compounds were 
converted to the corresponding guanidines by reaction with mercury(II) oxide and methanolic 
ammonia in chloroform to give 1N to 4N33,34 in 40 – 65% yield.35 Two iridium complexes9,36 based on 
these systems were prepared by reacting 2S and 2N separately with [Ir(ppy)2Cl]2 in toluene in the 
presence of potassium carbonate, giving bright yellow powders Ir-2S and Ir-2N in 53 % and 44 % yield 
respectively. All compounds were characterised by 1H and 13C NMR, EI-MS, and elemental analysis. 
To examine the biological activity of the compounds synthesised, they were tested for effects on the 
viability of the human ovarian cancer cell lines EFO-21, EFO-27 and COLO-704 and their cisplatin-
resistant sublines EFO-21rCDDP2000, EFO-27rCDDP2000 (both adapted to cisplatin 2µg/mL), and COLO-
704rCDDP1000 (adapted to cisplatin 1µg/mL) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphennyltetrazolium bromide) (MTT) assay modified after Mosmann37 as previously described.38 
Cisplatin is one of the most commonly used anticancer drugs, and resistance formation to cisplatin 
represents a major obstacle to the development of improved anticancer therapies.30,39,40. The assay 
principle is based on metabolization of the yellow MTT reagent into a purple insoluble formazan 
compound within the mitochondria of viable cells.37 This colour change from yellow to purple enables 
for the collection of rapid and coherent cell proliferation data.41 Concentrations that reduce cell 
viability by 50% relative to an untreated control (IC50) were calculated by treating the cell lines with 
sequential dilutions of the compounds. 
 
Figure 1. IC50 values for compounds 1S-4S and 1N-4N against six cancer cell lines. Error bars represent 
one standard deviation, over three repeats. 
All of the unmetallated compounds examined showed toxicity in all cell lines, with IC50 values in the 
low micromolar range (Fig. 1). While thioureas 1S, 2S, and 4S (IC50s across all cell lines averaging 1.29, 
1.26, and 2.96 μM, respectively) were notably more toxic than their guanidine counterparts 1N, 2N, 
and 4N (18.7, 10.1, 6.8 μM respectively), the hexyl-appended 3S (15.8 μM) was less effective at 
inhibiting cell proliferation than 3N (9.0 μM). We propose that these differences relate to the impact 
that the longer chain makes on the hydrophobicity balance of the molecule. The guanidine compounds 
are expected to be protonated under these conditions, and addition of a long chain will produce a 
cationic surfactant-type molecule which could disrupt biological membranes.42 With other side chains, 
the charged guanidiniums may not be sufficiently lipophilic to enter the biological membranes when 
compared to the neutral thioureas. This is supported by ClogP value calculation (Table S1, 
supplementary information) – only 3N (ClogP = 2.75) is as lipophilic as any of the S series (lowest ClogP 
is for 1S, at 2.58). In the case of 3S, the lipophilicity may be so high that it prevents the compound 
leaving the membrane and entering the cells. Despite the variation in activity of the individual 
compounds, the average sensitivity of the cell lines was remarkably consistent, with the parental EFO-
21, EFO-27, and COLO-704 lines have average IC50s of 8.0, 8.7, and 8.1 μM, and their cisplatin-resistant 
sublines having average IC50s of 14.5, 14.1, and 12.1 μM, respectively. Hence overall, the cisplatin 
resistant sublines were also more resistant to our compounds, however this effect was larger with 1N-
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 Figure 2. IC50 values for compounds Ir-2S and Ir-2N against six cancer cell lines. Error bars represent 
one standard deviation over three repeats. 
The same studies were then conducted with the iridium complexes Ir-2S and Ir-2N (Fig. 2). Here, the 
guanidine compound (average IC50 = 1.4 μM) was approximately ten times more toxic across the 
board than Ir-2S (average IC50 = 13.5 μM). This is a reverse of what was seen for the unmetallated 
compounds 2S and 2N. For both EFO-21 and EFO-27 lines, the cisplatin-resistant sublines were slightly 
more tolerant of all compounds (IC50s on average 25% higher), but when COLO-704rCDDP1000 cells 
were treated with Ir-2S the IC50 was reduced to 45% of the value of the parental cell line, suggesting 
that a different mechanism of resistance is in place here. In this case, both complexes are uncharged 
at pH 7, and since the chemical difference is on the interior of the molecule, they could be expected 
to have similar cell penetration properties, with the difference in toxicity being due to processing 
within the cell. 
 
Figure 3. Confocal images of cells treated with Ir-2S and Ir-2N. Emission from metal complexes are 
green, and nuclei are shown in blue (stained with DAPI). All cells were treated with compounds at their 
IC50 concentrations. The brightness, gain and excitation of the confocal microscopes laser for 
compound expression was kept consistent throughout the assays, although slight adjustments were 

























Taking advantage of the intrinsic luminescence of the iridium complexes, we were able to study 
whether the difference in toxicity related to cell uptake or internal processing using confocal 
microscopy (Fig. 3). Using EFO-21, EFO-21rCDDP2000, EFO-27, and EFO-27rCDDP2000 cells, which were 
amenable to this technique due to good adhesion properties, cell lines were dosed with Ir-2S and Ir-
2N at their IC50 concentrations. Ir-2S and Ir-2N have similar excitation and emission spectra in terms 
of peak position and shape, but the quantum yield of Ir-2N is roughly ten times that of Ir-2S (Fig. S1, 
supplementary information), since the IC50s of Ir-2S are approximately ten times higher than those 
of Ir-2N (Table S2, supplementary information), the total brightness for full uptake of either molecule 
should be similar, enabling comparison of uptake efficiency. Cell nuclei were stained with DAPI. In all 
cases, the compounds were observed to be primarily located in the cytoplasm, with little change in 
cell morphology compared to untreated cells. In EFO-21 and EFO-21rCDDP2000 cells, there was clearly 
greater uptake of the more toxic Ir-2N compared to Ir-2S. This is impressive given the tenfold 
difference in concentrations. In EFO-27 cells, the Ir-2N uptake was only slightly higher than that of Ir-
2S, while in EFO-27rCDDP2000 cells, the total level of uptake was approximately equal. However, in the 
latter case, distribution of Ir-2S was notably punctate compared to a more even distribution of Ir-2N. 
Whilst further analysis would be required to depict what may cause these discrepancies, this indicates 
cell line-specific differences in cellular uptake and intracellular distribution, which may cause the 
differences observed in toxicity. 
Conclusions 
All compounds tested showed notable toxicity. On the one hand, this shows that use of similar 
thiourea and guanidine structures in materials applications should be accompanied by caution about 
release. On the other hand, these structures could be useful scaffolds for cancer chemotherapeutics; 
in particular for drug resistance – the series 1S-4S showed minimal reduction in efficacy in drug 
resistant cell lines, and Ir-2S was in fact more effective in one resistant subline. Notably, cisplatin is a 
mainstay of ovarian cancer therapy. Although initial response is common, resistance formation and 
therapy failure are typically inevitable39,40,43. Hence, cisplatin-resistant ovarian cancer is an unmet 
clinical need and novel therapies are urgently needed. 
The mechanism of action of these compounds is unknown, but we have shown that uptake of the 
metal complexes at least is efficient. In summary, the investigated thiourea and guanidine derivatives 
uncovered promising low dose responses in the early research stages of human in vitro cell assays, 
with the data collected providing a start to new potential therapeutic pathways in the battle against 
drug-resistant ovarian cancer. 
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